Internet-CBT (Cognitive Behavioral Therapy) for Depression and Anxiety in Parkinsons Disease

February 12, 2015 updated by: Viktor Kaldo, Karolinska Institutet

Internet-based CBT for Depression and Anxiety in Parkinson's Disease: a Pilot Study and Randomized Controlled Trial

The purpose of this project is to develop and evaluate Internet-based Cognitive Behavioral Therapy (ICBT) for Parkinson's Disease (PD) patients with concurrent depression or anxiety symptoms. All treatment in this project is given as an adjunct to Standard Medical Treatment (SMT). ICBT will be compared to an Internet-based active control treatment (ICONTROL) and to SMT alone. It is hypothesized that both active treatments will be superior to SMT, and that ICBT will be superior to ICONTROL, in reducing symptoms of depression and anxiety.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden
        • Internetpsykiatrienehten (Internet Psychiatry Unit), Psykiatri Sydväst, SLSO

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of Parkinson's Disease
  • At least mild to moderate depression or anxiety defined as HADS-A or HADS-D > 7

Exclusion Criteria:

  • Has a high alcohol or drug use assessed by the AUDIT / DUDIT and assessment interview
  • Somatic or psychiatric problems that are directly contraindicated or seriously hamper the implementation of the treatment (eg, psychotic disorders or bipolar disorder)
  • Difficulties that hamper the use of a computer
  • The patient states difficulties in finding enough time for treatment
  • Too low cognitive functioning defined as MoCA < 24
  • Too severe depression, defined as MADRS-S over 30
  • Too high suicidal risk defined as more than 4 points on the MADRS-S question 9 or according to the structured assessment interview

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ICBT
Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
Active Comparator: ICONTROL
Internet-based treatment with a focus on relaxation training
12 weeks of Internet-based treatment with a focus on relaxation training
No Intervention: SMT
Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change (from baseline) in HADS
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
Hospital Anxiety and Depression Scale - self rating, to measure anxiety and depression
12 weeks (Post), 3 and 6 months (FU)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change (from baseline) in MADRS-S
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
Montgomery and Asberg Depressions Rating Scale - Self report, to measure level of depression
12 weeks (Post), 3 and 6 months (FU)
Change (from baseline) in ISI
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
Insomnia Severity Index - self-report, to measure insomnia symptoms
12 weeks (Post), 3 and 6 months (FU)
Change (from baseline) in PDQ-8
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
The Parkinson's Disease Questionnaire-8, to measure various health aspects specific for PD patients
12 weeks (Post), 3 and 6 months (FU)
Change (from baseline) in EQ-5D
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
EQ-5D, to measure general health and quality of life
12 weeks (Post), 3 and 6 months (FU)
Change (from baseline) in SDS
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
Sheehan Disability Scale, to measure everyday level of functioning
12 weeks (Post), 3 and 6 months (FU)
Change (from baseline) in NMSQuest
Time Frame: 12 weeks (Post), 3 and 6 months (FU)
Non-Motor Symptoms Questionnaire, to measure the non-motor symptoms in PD
12 weeks (Post), 3 and 6 months (FU)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Viktor Kaldo, Ph.D., Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

August 1, 2013

Study Registration Dates

First Submitted

March 1, 2012

First Submitted That Met QC Criteria

March 5, 2012

First Posted (Estimate)

March 6, 2012

Study Record Updates

Last Update Posted (Estimate)

February 13, 2015

Last Update Submitted That Met QC Criteria

February 12, 2015

Last Verified

February 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on ICBT

Subscribe